^
BIOMARKER:

MLL rearrangement

i
Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
MLL rearrangement
AML
palbociclib
Sensitive: C2 – Inclusion Criteria
MLL rearrangement
AML
venetoclax
Sensitive: C2 – Inclusion Criteria
MLL rearrangement
AML
abemaciclib
Sensitive: C3 – Early Trials
MLL rearrangement
ALL
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
MLL rearrangement
ALL
inotuzumab ozogamicin
Resistant: C3 – Early Trials
MLL rearrangement
AML
KO-539
Sensitive: C3 – Early Trials
MLL rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Resistant: C3 – Early Trials
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MK-2206
Sensitive: D – Preclinical
MLL rearrangement
B Acute Lymphoblastic Leukemia
venetoclax
Sensitive: D – Preclinical
MLL rearrangement
Leukemia
JQ-1
Sensitive: D – Preclinical